Vericel CORP 10-Q quarterly reports

Vericel Corporation announced a significant increase in total revenue for the second quarter of 2026, driven by robust performance in its MACI and Epicel product lines, alongside positive operational cash flow.

Vericel Corporation announced a 30.1% increase in total revenue for the first quarter of 2026, driven by significant growth in MACI and Epicel sales.

Vericel Corporation reported a significant turnaround to net income in Q3 2025, driven by robust MACI sales and NexoBrid growth, despite a decline in Epicel revenue.

Vericel Corporation announced a significant increase in total revenue for the first half of 2025, fueled by strong performance in its MACI and NexoBrid products, though the company's net loss widened due to increased operating expenses.

Vericel Corporation's Q1 2025 results show revenue growth driven by MACI and NexoBrid, offset by a decline in Epicel sales, resulting in a net loss of $11.2 million.

Vericel Corporation's Q3 2024 results show a significant increase in revenue, primarily driven by growth in MACI and burn care product sales, alongside the launch of MACI Arthro.

Vericel Corporation's Q2 2024 results show a 14.7% increase in total revenue compared to Q2 2023, driven by growth in MACI and the introduction of NexoBrid.

Vericel Corporation's first quarter 2024 results show a 25% increase in total revenue compared to the same period last year, driven by growth in MACI, Epicel, and the introduction of NexoBrid.